SK285129B6 - Preparát na orálnu aplikáciu s kontrolovaným uvoľňovaním opioidného analgetika - Google Patents

Preparát na orálnu aplikáciu s kontrolovaným uvoľňovaním opioidného analgetika Download PDF

Info

Publication number
SK285129B6
SK285129B6 SK64-2000A SK642000A SK285129B6 SK 285129 B6 SK285129 B6 SK 285129B6 SK 642000 A SK642000 A SK 642000A SK 285129 B6 SK285129 B6 SK 285129B6
Authority
SK
Slovakia
Prior art keywords
crystals
coating
preparation according
opioid analgesic
retarding
Prior art date
Application number
SK64-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK642000A3 (en
Inventor
Johannes Heinrich Bartholom�Us
J�Rgen Betzing
Original Assignee
Grnenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grnenthal Gmbh filed Critical Grnenthal Gmbh
Publication of SK642000A3 publication Critical patent/SK642000A3/sk
Publication of SK285129B6 publication Critical patent/SK285129B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK64-2000A 1999-01-18 2000-01-17 Preparát na orálnu aplikáciu s kontrolovaným uvoľňovaním opioidného analgetika SK285129B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901687A DE19901687B4 (de) 1999-01-18 1999-01-18 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung

Publications (2)

Publication Number Publication Date
SK642000A3 SK642000A3 (en) 2000-08-14
SK285129B6 true SK285129B6 (sk) 2006-07-07

Family

ID=7894566

Family Applications (1)

Application Number Title Priority Date Filing Date
SK64-2000A SK285129B6 (sk) 1999-01-18 2000-01-17 Preparát na orálnu aplikáciu s kontrolovaným uvoľňovaním opioidného analgetika

Country Status (24)

Country Link
US (1) US6685964B1 (es)
EP (1) EP1020185B1 (es)
JP (1) JP2000212072A (es)
KR (1) KR20000071247A (es)
CN (1) CN1244327C (es)
AR (1) AR022254A1 (es)
AT (1) ATE257012T1 (es)
AU (1) AU771064B2 (es)
CA (1) CA2295471A1 (es)
CO (1) CO5251462A1 (es)
DE (2) DE19901687B4 (es)
DK (1) DK1020185T3 (es)
ES (1) ES2213971T3 (es)
HK (1) HK1029749A1 (es)
HU (1) HUP0000138A3 (es)
IL (1) IL134076A (es)
NZ (1) NZ502261A (es)
PE (1) PE20001395A1 (es)
PL (1) PL337867A1 (es)
PT (1) PT1020185E (es)
RU (1) RU2239417C2 (es)
SI (1) SI1020185T1 (es)
SK (1) SK285129B6 (es)
ZA (1) ZA200000173B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
PT1190712E (pt) * 2000-09-22 2005-01-31 Smb Technology Composicao de esferas de tramadol para administracao oral uma vez por dia
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2002303718B2 (en) * 2001-05-11 2008-02-28 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2003219680A1 (en) * 2002-01-23 2003-09-02 The Regents Of The University Of California Methods and compositions for reducing the development of drug tolerance and/or physical dependence
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
AU2003271024A1 (en) * 2002-09-21 2004-04-08 Jin Wang Sustained release compound of acetamidophenol and tramadol
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
CN100336501C (zh) * 2003-08-06 2007-09-12 健乔信元医药生技股份有限公司 醋炎痛缓释性圆粒组成物及制备方法
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
EP1754471A1 (de) * 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
CA2644435C (en) * 2006-03-06 2015-04-07 Pozen Inc. Dosage forms for administering combinations of drugs
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
GB0625646D0 (en) * 2006-12-21 2007-01-31 Jagotec Ag Improvements in or relating to organic compounds
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
GB0714790D0 (en) * 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
US20120065221A1 (en) * 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CN106176683B (zh) * 2016-08-31 2019-04-16 贵州益康制药有限公司 一种盐酸曲马多缓释胶囊及其制备方法和用途
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2024193475A1 (zh) * 2023-03-17 2024-09-26 浙江大学 一种控释制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
IE59287B1 (en) * 1984-02-10 1994-02-09 Benzon Pharma As Diffusion coated multiple-units dosage form
US5095151A (en) * 1985-05-21 1992-03-10 American Home Products Corporation Preparation of propranolol hydrochloride macrocrystals
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
HU218673B (hu) 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
EP0654263B1 (en) * 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung

Also Published As

Publication number Publication date
US6685964B1 (en) 2004-02-03
CA2295471A1 (en) 2000-07-18
HK1029749A1 (en) 2001-04-12
EP1020185B1 (de) 2004-01-02
HUP0000138A3 (en) 2001-03-28
EP1020185A2 (de) 2000-07-19
PE20001395A1 (es) 2000-12-23
IL134076A (en) 2005-05-17
IL134076A0 (en) 2001-04-30
SI1020185T1 (en) 2004-04-30
PT1020185E (pt) 2004-05-31
HU0000138D0 (en) 2000-03-28
DE19901687B4 (de) 2006-06-01
AR022254A1 (es) 2002-09-04
DE59908195D1 (de) 2004-02-05
AU1011300A (en) 2000-07-20
ES2213971T3 (es) 2004-09-01
NZ502261A (en) 2001-11-30
EP1020185A3 (de) 2000-09-27
CN1270029A (zh) 2000-10-18
SK642000A3 (en) 2000-08-14
CN1244327C (zh) 2006-03-08
HUP0000138A2 (hu) 2001-02-28
ATE257012T1 (de) 2004-01-15
ZA200000173B (en) 2000-08-07
DK1020185T3 (da) 2004-02-16
AU771064B2 (en) 2004-03-11
PL337867A1 (en) 2000-07-31
RU2239417C2 (ru) 2004-11-10
DE19901687A1 (de) 2000-07-20
KR20000071247A (ko) 2000-11-25
JP2000212072A (ja) 2000-08-02
CO5251462A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
SK285129B6 (sk) Preparát na orálnu aplikáciu s kontrolovaným uvoľňovaním opioidného analgetika
EP2136793B1 (en) Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
JP2002534458A (ja) オピオイド及びα−アゴニストを含有する薬剤
EP1555022A1 (en) Sustained release compound of acetamidophenol and tramadol
AU778151B2 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
JP5948648B2 (ja) 安定化されたエペリゾンを含有する徐放性製剤
CN101977593A (zh) 包含弱碱性药物以及有机酸的给药系统
WO2013092589A1 (en) Multiple unit pellet tablet formulation comprising an opioid
SK652000A3 (en) Orally applicable composition of analgesics with controlled release of an active substance
SK50442006A3 (sk) Pelety obsahujúce hydrochlorid venlafaxínu
JP2020073583A (ja) ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形
AU2020202055B2 (en) Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2006247357B2 (en) Morphine sulfate formulations
CZ2000171A3 (cs) Orálně aplikovatelný preparát opioidních analgetik s kontrolovaným uvolňováním účinné látky
US20120082718A1 (en) Morphine Formulations
MXPA00000604A (es) Analgesico opioides con liberacion controlada de la sustancia activa
MXPA01006899A (es) Formulaciones medicinales que contienen un opioide y un alfa antagonista
CZ2000170A3 (cs) Orálně aplikovatelný preparát analgetika s kontrolovaným uvolňováním účinné látky
MXPA00000605A (es) Formulaciones medicinales retardadas que contienen una combinacion de un opioide y un alfa-agonista

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140117